Ligustrazine Injection for Chronic Pulmonary Heart Disease: A Systematic Review and Meta-Analysis
Ligustrazine Injection for Chronic Pulmonary Heart Disease: A Systematic Review and Meta-Analysis
复制标题
川芎嗪注射液治疗慢性肺心病：系统评价与荟萃分析
DOI：
10.1155/2012/792726
复制
发表时间：
2011-08
影响因子：
--
通讯作者：
Li Ya
中科院分区：
文献类型：
--
作者：
Li Jian-sheng;Wang Hai-feng;Bai Yun-ping;Li Su-yun;Yu Xue-qing;Li Ya
Objective.本研究旨在评价川芎嗪注射液治疗慢性肺心病的有效性和安全性。法纳入川芎嗪注射液治疗慢性肺心病临床研究的随机对照试验。将检索表应用于以下电子数据库：PubMed、科克伦图书馆、EMBASE、CBM和AMED。没有语言限制。根据科克伦手册的标准对纳入的所有试验进行分析。使用Review Manager 5.0软件进行数据分析。结果.纳入了34项方法学质量较低的RCT。与单纯常规药物治疗相比，川芎嗪注射液联合常规药物治疗显示纽约心脏协会临床状态分类（比值比0.22; 95%CI 0.17 - 0.28）和肺动脉高压抑制（加权平均差异-4.77; 95%CI-5.85至3.68）改善。三项研究报告了不良事件。未报告严重不良反应。结论虽然有一些证据表明川芎嗪注射液对CPHD的潜在有效性，但研究方法的缺陷限制了结果。需要高质量的研究为川芎嗪注射液的未来使用提供明确的证据。
Objective. This study was intended to evaluate the efficacy and safety of ligustrazine injection for chronic pulmonary heart disease (CPHD). Method. Randomized controlled trials (RCTs) of clinical therapeutic studies on CPHD when using ligustrazine injection were included. Searches were applied to the following electronic databases: the PubMed, the Cochrane Library, EMBASE, CBM, and AMED. No language restriction was used. All trials included were analyzed according to the criteria of the Cochrane Handbook. Review Manager 5.0 software was used for data analysis. Result. 34 RCTs with low methodological quality were included. Compared to conventional medicine treatment alone, ligustrazine injection plus conventional medicine treatment showed improvement in New York Heart Association classification of clinical status (Odds ratio 0.22; 95% CI 0.17 to 0.28) and depression of pulmonary artery hypertension (weighted mean difference −4.77; 95% CI −5.85 to −3.68). Three studies had reported adverse events. No serious adverse effects were reported. Conclusion. While there is some evidence that suggests potential effectiveness of ligustrazine injection for CPHD, the results were limited by the methodological flaws of the studies. High quality studies are needed to provide clear evidence for the future use of ligustrazine injection.
DOI：
10.1016/0197-2456(95)00134-4
发表时间：
1996-02-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
Jadad, AR;Moore, RA;McQuay, HJ
通讯作者：
McQuay, HJ
基于证据的补充和替代医学：审阅者清单
DOI：
10.1093/ecam/nen076
发表时间：
2008-11-19
期刊：
Evidence-based Complementary and Alternative Medicine : eCAM
影响因子：
--
作者：
通讯作者：
--